Clinical trials
Immunotherapy clinical trials
Below are recruiting immunotherapy clinical trials, each written for real people, not researchers. We’re tracking 747 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06842407Recruiting
Blood donation study for antibody therapy research
This trial is collecting blood samples from healthy donors to help researchers develop new antibodies for immune-based therapies (immunotherapy). It may lead to new treatments for various conditions.
MilanAges 18 years+ - NCT06835140RecruitingPhase 1
NK cell immunotherapy for AML that has stopped responding to treatment
This trial tests a new type of immunotherapy using special immune cells (NK cells) that target the CD123 marker found on AML cells. It may help people whose AML has not responded to standard treatments and who have a healthy donor available.
Beijing, ChinaAges 18–70 - NCT07369882Recruiting
Less extensive surgery after immunotherapy for advanced head and neck cancer
This trial compares a less extensive surgery to the standard surgery for patients with advanced head and neck cancer who have responded well to initial chemotherapy and immunotherapy. The goal is to see if a smaller operation can be just as effective while causing fewer side effects.
Guangzhou, GuangdongAges 18–75 - NCT07357636Recruiting
Immune therapy side effects study for solid tumors
This study looks at side effects from immune checkpoint inhibitors in people with solid tumors. It aims to understand why side effects happen and who might be at risk, so doctors can better manage them.
Fuzhou, FujianAges 18 years+ - NCT07354100RecruitingPhase 1/Phase 2
Lactulose to boost gut health during immunotherapy
This study tests whether a simple sugar syrup called lactulose can improve gut health and make immunotherapy work better for certain cancers. Lactulose is taken by mouth along with your regular immunotherapy.
Chicago, IllinoisAges 18 years+ - NCT07360743RecruitingPhase 2
Immunotherapy alone for advanced lung cancer with high PD-L1
This trial tests whether using immunotherapy drugs (pembrolizumab or cemiplimab) alone, without chemotherapy, can treat advanced lung cancer in people with high PD-L1 levels. It is for people who have not yet received any treatment for their advanced cancer.
BordeauxAges 18 years+ - NCT07359040Recruiting
Testing a new drug before surgery for lung cancer
This trial studies whether a new drug called Ivonescimab can improve outcomes when given before surgery for non-small cell lung cancer. It may help shrink tumors and make them easier to remove.
Beijing, Beijing MunicipalityAges Any age - NCT07359183Recruiting
Long-term follow-up of kids who had oral immunotherapy for allergies
This study checks on children and young people 5 to 15 years after they finished an 18-month oral immunotherapy treatment for peanut, egg, or milk allergy. It helps researchers understand how their allergies and health are doing over the long term.
Parkville, VictoriaAges Any age - NCT07354971Recruiting
Immuno-fit study for patients on immunotherapy
This study looks at how well patients with solid tumors who are receiving immunotherapy (checkpoint inhibitors) can exercise. It aims to see if exercise testing can help track your health during treatment.
Southampton, HampshireAges 18 years+ - NCT05652673Recruiting
Stopping immunotherapy after a good melanoma response
This trial studies whether it’s safe to stop nivolumab (an immunotherapy) after your melanoma has responded well to initial treatment with ipilimumab plus nivolumab. It may help some people avoid ongoing treatment side effects while still keeping the cancer controlled.
RotterdamAges 18 years+ - NCT06784778Recruiting
Testing a blood test to predict immunotherapy response
This study is testing a new blood test called IOpener®-Melanoma to see if it can predict which patients with advanced melanoma will respond well to immunotherapy. The goal is to better match treatments to people who will benefit most.
Tübingen, Baden-WurttembergAges 18 years+ - NCT06851299RecruitingPhase 2
Trop2-ADC alone or with immunotherapy for advanced triple-negative breast cancer
This study tests a new drug called Trop2-ADC, either alone or combined with immunotherapy, for people with advanced triple-negative breast cancer. The goal is to see if it can shrink tumors and improve outcomes.
Guangzhou, GuangdongAges 18–70 - NCT06849518Recruiting
Blood test to track immunotherapy response in lung cancer
This study is looking at a simple blood test to see if it can help track how well your immunotherapy is working. If you have advanced lung cancer and are getting a standard immunotherapy drug, you may be able to join.
Kingsport, TennesseeAges Any age - NCT06853678Recruiting
Immunotherapy after first treatment for extensive stage small cell lung cancer
This trial tests immunotherapy drugs for extensive stage small cell lung cancer that has progressed after initial (first-line) chemotherapy. You may be eligible if you have finished standard treatment and your cancer has worsened.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT06845592Recruiting
Stronger radiation and cell therapy before stem cell transplant for high-risk leukemia
This trial tests a special transplant approach for people with high-risk acute leukemia. It uses a stronger dose of radiation before transplant, followed by an infusion of immune cells (regulatory and conventional T cells) to help the transplant work better and fight the leukemia.
Perugia, PGAges 18–65 - NCT07348302RecruitingPhase 3
Allergy tablet for dust mite rhinitis and asthma
This trial tests an under-the-tongue tablet for people with dust mite allergies causing moderate to severe nasal symptoms or mild-to-moderate asthma. The goal is to see if it improves symptoms and can replace or reduce the need for allergy medicines.
Nueve de Julio, Buenos AiresAges 12–65 - NCT07347951RecruitingPhase 2
New drug combo for rectal cancer patients who want to save their anus
This trial tests a combination of short-course radiation, chemotherapy, and two targeted drugs (Serplulimab and Bevacizumab) for people with a specific type of rectal cancer. It aims to see if this treatment can help shrink the tumor enough to avoid surgery and keep the anus.
Wenzhou, ZhejiangAges 18–75 - NCT07343596Recruiting
Immunotherapy before surgery for oral cavity cancer
This study tests whether giving an immunotherapy drug called pembrolizumab before surgery can help treat oral cavity cancer. The researchers will look for biomarkers (clues in your tumor) that may predict how well the treatment works.
Madison, WisconsinAges 18 years+ - NCT07343986RecruitingPhase 1
Ultrasound and Immunotherapy for Newly Diagnosed Brain Cancer
This trial tests whether a special ultrasound (LIFU) can open the blood-brain barrier to help an immunotherapy drug (cetuximab) reach glioblastoma tumors better. It is for people with a specific type of glioblastoma that has not been treated yet and that has a certain protein called EGFR.
Charlottesville, VirginiaAges 18–70 - NCT07334483RecruitingPhase 2
Radiation plus targeted immunotherapy for liver cancer
This trial tests a combination of radioactive microspheres (Yttrium-90) with targeted immunotherapy drugs (camrelizumab and apatinib) for people with liver cancer (HCC) that cannot be surgically removed. It may be an option for those with intermediate-stage disease who haven't had prior systemic therapy.
BeijingAges 18–75 - NCT07337096Recruiting
Electro-acupuncture for advanced lung cancer: the EALER study
This study tests whether adding electro-acupuncture (a gentle type of acupuncture with mild electrical pulses) to standard first-line immunotherapy and chemotherapy can help people with advanced non-small cell lung cancer. It aims to see if this combination improves quality of life and overall treatment outcomes.
Guangzhou, GuangdongAges 18 years+ - NCT07342283RecruitingPhase 2
QL1706 plus chemo before surgery for triple-negative breast cancer
This trial tests a combination of an immunotherapy drug (QL1706) plus standard chemotherapy given before surgery to shrink triple-negative breast cancer. The goal is to see if this approach helps remove the tumor more completely.
Nantong, JiangsuAges 18 years+ - NCT06499480Recruiting
Italian registry of allergy shots and drops
This trial collects information from people of all ages who have allergic rhinitis, conjunctivitis, or asthma and are prescribed allergy immunotherapy (shots or drops). The goal is to understand how these treatments work in real life.
Rozzano, MilanoAges 1 year+ - NCT07328841RecruitingPhase 3
Lower radiation dose study for advanced nasopharyngeal cancer
This trial compares a lower dose of radiation to the standard dose for people with advanced nasopharyngeal cancer that shrank after chemotherapy and immunotherapy. The goal is to see if a lower dose works just as well with fewer side effects.
Guangzhou, GuangdongAges 18–70
Hear when a new Immunotherapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for immunotherapy?
- Yes. Clin2 currently lists 747 recruiting immunotherapy studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a immunotherapy trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a immunotherapy trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.